Progress in understanding variability in cognitive responses to cholinesterase inhibitor treatment
Limitations on the duration of clinical trials, and the constraints of participant selection for such studies, have left many unanswered questions regarding the optimal duration of drug treatment for Alzheimer's disease patients, as well as the subgroups of patients that benefit most. Carefully...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2011
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218807/ |